Abstract
Background: Psoriasis is an autoinflammatory disease that affects not only skin, but multiple organs thus being associated with many comorbidities. Oxidative stress and inflammation play the major role in the pathogenesis of this disease. Studies that examined by-products of oxidative stress in psoriasis show discrepant results. Hence, we aimed to examine the oxidative stress, inflammation and metabolic markers and to explore their potential relationship with disease severity in patients with psoriasis.
Methods: This case-control study comprised of 35 patients with psoriasis and 35 age, sex and body mass index-matched healthy controls. Metabolic and oxidative stress biomarkers [i.e., malondialdehyde (MDA), advanced oxidation protein products (AOPP), and catalase (CAT)] were measured. The principal component analysis (PCA) was employed to reduce the number of measured variables into smaller number of factors.
Results: Higher AOPP levels (p<0.01) and CAT activity (p<0.001), but no difference in MDA levels in psoriasis patients vs. healthy controls were shown. Multivariate binary logistic regression analysis showed that a combination of metabolic related factor (i.e., glucose and triglycerides) and renal function related factor (i.e., creatinine and urea) was the best model for Psoriasis Area and Severity Index (PASI) >10 prediction, while oxidative stress-hepatic related factor (i.e., MDA, alanine aminotransferase) was selected as the best predictor for Dermatology Life Quality Index (DLQI) >20.
Conclusion: Multimarker approach showed that metabolic and renal function related factor and oxidative stress-hepatic related factor were better predictors of psoriasis severity than each single examined biomarker.
Keywords
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.